Rhythm Pharmaceuticals has delivered a very large 5 year return, yet its latest valuation checks and current trading multiples point to a stock that may now be pricing in a lot of optimism after the recent news on IMCIVREE and RM-718.

• Rhythm Pharmaceuticals has returned about 7.99x over 5 years, which puts extra focus on whether recent gains are supported by fundamentals rather than momentum alone.
• Regulatory progress for IMCIVREE and encouraging RM-718 trial data can support expectations for future revenue, while execution risk around broader adoption, reimbursement and further approvals may weigh on how much investors are willing to pay today.
• The stock currently screens as overvalued on market multiples and holds a mixed valuation profile overall, with 3 out of 6 checks suggesting it is not clearly cheap or clearly expensive.

For investors, the debate is whether Rhythm Pharmaceuticals’ recent share price level already reflects the good news on IMCIVREE and RM-718 or still leaves room for further upside before the valuation looks stretched.

Does Rhythm Pharmaceuticals Look Pricey on Sales?

P/S is usually a straightforward way to compare Rhythm Pharmaceuticals to other biotechs, since many companies in this space are still moving toward consistent earnings.

Rhythm Pharmaceuticals currently trades on a P/S of about 33.1x. That is much higher than both the broader biotech industry average of 10.9x and a peer group average of 9.1x. On a simple sales basis, the stock is pricing in more value per dollar of revenue than many other biotechs.

The tailored fair P/S ratio for Rhythm Pharmaceuticals is around 19.7x, which is below the current 33.1x level. In light of the recent positive updates on IMCIVREE and RM-718, this gap indicates that investors are paying a premium relative to what this model implies for the company’s growth profile and risks.

Overall, Rhythm Pharmaceuticals appears expensive on its current P/S multiple compared with both industry norms and its own fair ratio estimate.

The Rhythm Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Rhythm Pharmaceuticals pick up where the P/S discussion leaves off and spell out what would need to happen to growth, margins and earnings for the current share price to look conservative or demanding. Each scenario links its implied valuation to a specific view on how Rhythm Pharmaceuticals' revenue potential, profitability and key risks might evolve. You can revisit these scenarios as new clinical or financial data becomes available.

One of the top community narratives on Rhythm Pharmaceuticals: 14% undervalued

"Having expanded from one disorder to multiple approved indications, the company has additional opportunities ahead to expand its portfolio..."

Do you think there's more to the story for Rhythm Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Rhythm Pharmaceuticals now trades on a premium P/S multiple that screens as overvalued relative to both peers and its own tailored sales ratio. The valuation already bakes in a lot of confidence in broader IMCIVREE adoption and the RM-718 opportunity. For you as an investor, the key question is whether future execution on reimbursement, label expansion and real world uptake is strong enough to keep that premium intact, or whether the market eventually demands a lower multiple if progress is slower than hoped.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.